Home / Solutions
Our solutions
Leveraging precision-cut tissue slices (PCTS), we help drug developers generate human-relevant evidence, increasing preclinical decision confidence and reducing translational uncertainty.
Don’t approximate human biology, test it
Surrogate models fail to produce reliable data. In-vitro cell cultures and organoids fail to recreate tissue complexity and therapeutic responses in animal models are rarely replicated in the clinic.
Human tissue provides a more translatable platform to understand therapeutic response in real human disease.
FibroFind’s PCTS platform bridges the gap by enabling studies in viable, intact human tissue, supporting translational confidence, portfolio prioritisation and earlier go or no-go decisions.
Target identification and validation
Interrogate novel therapeutic targets in intact, viable human tissue to build the real biological evidence needed to support confident early decisions.
Lead screening and optimization
Test and rank novel interventions early to generate the decision-grade data needed to prioritise stronger candidates and reduce preclinical risk.
Pharmacology
Gain direct evidence of target engagement in intact human tissue to strengthen the translational case behind your program and support IND-enabling submissions.
Drug safety
Assess tissue viability and emerging safety signals in intact human tissue to identify weak assets early and avoid unnecessary progression into formal GLP studies.
Make your next decision with confidence
Find out how we replace biological guesswork with clarity, giving high-potential assets the best chance to reach patients.
The new standard
Combining the benefits of ex-vivo PCTS and our proprietary bioreactor technology, our platform generates credible, human-relevant evidence to de-risk your drug discovery and development to support stronger preclinical decisions.
Tissue bioreactor technology
Proprietary bioreactor systems designed to preserve native tissue structure and function, enabling controlled, extended study in living human tissue.
Tissue types and indications
Ethical procurement of viable human liver, lung and kidney tissue through established clinical partnerships for use in our PCTS platforms.
Because attrition costs
With fewer than 10% of drug candidates reaching approval, every preclinical decision carries significant capital and reputational consequences. Advancing the wrong asset on the basis of uncertain data compounds that risk substantially.
Rather than relying on simplified cell culture systems or costly animal models, our bioreactor-supported PCTS platform enables drug response to be studied directly in viable, intact human tissue.
We help underpin your strategy with the defensible, human-relevant evidence required to protect asset valuation, drive capital efficiency and secure project funding.
The evidence your program demands
Speak to our team about your programme.